Graph Therapeutics has raised $5M, bringing total funding to over $10M, to develop its own drugs for inflammatory and immune diseases.
The Vienna-based startup was founded by the team behind Allcyte, the AI drug discovery company Exscientia acquired for $60M in June 2021.
Paris-based Daphni, backer of unicorns Back Market, Swile, and BlaBlaCar, joins the round as a new investor.
When Exscientia paid $60M for Allcyte in June 2021, it was buying one specific idea: that testing drugs against living tissue from real patients would outperform every artificial proxy the industry relied on.
Gregory Vladimer, who co-founded Allcyte and helped prove that idea in cancer, has a new company. His new company, Graph Therapeutics, applies that same approach to a harder problem, and has now raised $5M to stop licensing its platform and start developing its own medicines, bringing total funding to over $10M.
